Patient Satisfaction and Regret After Robot-assisted Radical Prostatectomy: A Decision Regret Analysis
Patient Satisfaction and Regret After Robot-assisted Radical Prostatectomy: A Decision Regret Analysis
复制标题
DOI：
10.1016/j.urology.2020.12.015
复制
发表时间：
2021-03-05
期刊：
影响因子：
2.1
通讯作者：
Kusuma, Venkata R. M.
中科院分区：
文献类型：
--
作者：
Lindsay, Jamie;Uribe, Santiago;Kusuma, Venkata R. M.
目的评估机器人辅助根治性直肠癌切除术（RARP）后的治疗满意度和决策后悔，并将其与临床、人口统计学和生活质量指标相关联。我们的研究发生在一个高容量的英国中心和患者进行了评估，在至少18个月postsurgery. METHODS患者接受RARP在2011年6月和2016年5月之间被邀请参加通过邮寄问卷。共有207名患者组成了我们的队列。问卷包括欧洲癌症研究与治疗组织癌症患者生活质量30和PR25模块、男性性健康量表和Likert决策后悔量表。A决策后悔量表得分> 15被用来定义一个结果的高决策regret.Results患者的平均年龄为63岁，平均随访时间为36个月。在106名应答者中，51名（48%）对接受RARP的决定完全满意，32名（30%）记录了高度遗憾。平均决策后悔量表评分为11.3。高决策遗憾与RARP问卷管理的时间长度，前列腺特异性生活质量的症状评分较高，较低的性和勃起功能scores.CONCLUSION我们的研究代表了第一个当代英国系列评估决策遗憾后，管理局部前列腺癌与RARP。在三分之一的患者中观察到更高的后悔，并且与更差的疾病特异性生活质量，性和勃起功能指标相关。为了尽量减少遗憾，在术前就RARP向患者提供咨询时，应进行合作和详细的讨论。应明确这些副作用的潜在寿命和对生活质量的影响。(C)2020爱思唯尔公司
OBJECTIVE To assess treatment satisfaction and decision regret post robot-assisted radical prostatectomy (RARP) and correlate these with clinical, demographic and quality of life indicators. Our study took place at a high-volume United Kingdom center and patients were assessed at a minimum of 18 months postsurgery.METHODS Patients who underwent RARP between June 2011 and May 2016 were invited to participate through mailed questionnaires. A total of 207 patients formed our cohort. The questionnaires included European Organization for Research and Treatment of Cancer Quality of Life of Cancer patients 30 and PR25 modules, sexual health inventory in men and Likert decisional regret scale. A Decisional Regret Scale score of >15 was used to define an outcome of high decision regret.RESULTS The mean patient age was 63 years and the mean duration of follow up was 36 months. Of the 106 responders, 51 (48%) were fully satisfied with the decision to undergo RARP and 32 (30%) recorded high regret. The mean Decisional Regret Scale score was 11.3. High decision regret associated with the length of time from RARP to questionnaire administration, higher prostate specific quality of life symptom scores and lower sexual and erectile function scores.CONCLUSION Our study represents the first contemporary United Kingdom series assessing decision regret following the management of localised prostate cancer with RARP. Higher regret was seen in one third of patients and was associated with worse disease-specific quality of life, sexual and erectile function measures. To minimize regret, collaborative and detailed discussion should take place pre-operatively when counselling patients about RARP. The potential longevity and impact on quality of life of these side effects should be made clear. (C) 2020 Elsevier Inc.